Competition record
Endo
Deep profile · 1 linked library matter
Endo is a branded and generic drug company named in a settled FTC matter with Watson and Teva. The dispute was a pay-for-delay case from the period when opioid pain drugs were a large part of the branded business.
Overview
Endo sells branded medicines and generics. In the opioids era its branded pain franchise was a major part of the company. The company has also been through bankruptcy.
The Federal Trade Commission challenged pay-for-delay settlements in which Endo resolved patent fights with generic makers, including Watson and Teva, in ways the agency said kept cheaper copies off the market. The library's account centers on delay of a generic pain patch. Paying a generic company to stay out shares the branded profit instead of letting the generic launch.
The library status is settled. Endo resolved the FTC matter alongside Watson and Teva. The settlement is the recorded end of the pay-for-delay claim.
Competition footprint
A pay-for-delay deal postpones the generic that would cut the branded price.
Watson and Teva are the generic companies named with Endo in the library file.
Settlement is the status, and it is not a stated damages number.
Consumer & business angle
Patients and insurers paid the branded price for longer.
Generic manufacturers were the firms whose entry the settlements delayed.
What to watch
- How the FTC settlement limits later patent deals by the same company.
- The bankruptcy estate's handling of drug-pricing liabilities, which is separate from the FTC status recorded here.
Markets
branded drugs · generic drugs · prescription pharmaceuticals · topical pain patches
Also known as: endo pharmaceuticals, endo international